Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKCD_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKCD_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKCD_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCD_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCD_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCD_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903311112 | Thyroid | PTC | regulation of mRNA metabolic process | 181/5968 | 288/18723 | 1.60e-27 | 5.94e-25 | 181 |
GO:0032386111 | Thyroid | PTC | regulation of intracellular transport | 202/5968 | 337/18723 | 1.12e-26 | 3.93e-24 | 202 |
GO:0033157112 | Thyroid | PTC | regulation of intracellular protein transport | 149/5968 | 229/18723 | 3.83e-25 | 1.15e-22 | 149 |
GO:0006913112 | Thyroid | PTC | nucleocytoplasmic transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
GO:0051169112 | Thyroid | PTC | nuclear transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
GO:0032388112 | Thyroid | PTC | positive regulation of intracellular transport | 132/5968 | 202/18723 | 1.10e-22 | 2.57e-20 | 132 |
GO:0031647113 | Thyroid | PTC | regulation of protein stability | 174/5968 | 298/18723 | 2.05e-21 | 4.05e-19 | 174 |
GO:0034504111 | Thyroid | PTC | protein localization to nucleus | 170/5968 | 290/18723 | 3.34e-21 | 6.38e-19 | 170 |
GO:0090316110 | Thyroid | PTC | positive regulation of intracellular protein transport | 109/5968 | 160/18723 | 4.20e-21 | 7.79e-19 | 109 |
GO:0006401112 | Thyroid | PTC | RNA catabolic process | 163/5968 | 278/18723 | 2.13e-20 | 3.27e-18 | 163 |
GO:1903829113 | Thyroid | PTC | positive regulation of cellular protein localization | 162/5968 | 276/18723 | 2.40e-20 | 3.52e-18 | 162 |
GO:2001233113 | Thyroid | PTC | regulation of apoptotic signaling pathway | 197/5968 | 356/18723 | 2.58e-20 | 3.69e-18 | 197 |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:0097193113 | Thyroid | PTC | intrinsic apoptotic signaling pathway | 164/5968 | 288/18723 | 9.17e-19 | 1.09e-16 | 164 |
GO:0006402112 | Thyroid | PTC | mRNA catabolic process | 139/5968 | 232/18723 | 9.59e-19 | 1.12e-16 | 139 |
GO:0051098113 | Thyroid | PTC | regulation of binding | 195/5968 | 363/18723 | 3.21e-18 | 3.37e-16 | 195 |
GO:1904951113 | Thyroid | PTC | positive regulation of establishment of protein localization | 175/5968 | 319/18723 | 1.10e-17 | 1.12e-15 | 175 |
GO:1902903113 | Thyroid | PTC | regulation of supramolecular fiber organization | 202/5968 | 383/18723 | 1.16e-17 | 1.15e-15 | 202 |
GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
GO:0034655112 | Thyroid | PTC | nucleobase-containing compound catabolic process | 211/5968 | 407/18723 | 2.72e-17 | 2.52e-15 | 211 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCD | SNV | Missense_Mutation | novel | c.1115N>T | p.Gly372Val | p.G372V | Q05655 | protein_coding | deleterious(0.01) | benign(0.342) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PRKCD | SNV | Missense_Mutation | novel | c.548A>T | p.Asn183Ile | p.N183I | Q05655 | protein_coding | deleterious(0.03) | probably_damaging(0.985) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCD | SNV | Missense_Mutation | | c.1573N>A | p.Tyr525Asn | p.Y525N | Q05655 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PRKCD | SNV | Missense_Mutation | rs781980599 | c.277N>A | p.Glu93Lys | p.E93K | Q05655 | protein_coding | deleterious(0.02) | benign(0.407) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
PRKCD | SNV | Missense_Mutation | novel | c.609N>C | p.Lys203Asn | p.K203N | Q05655 | protein_coding | tolerated(0.21) | possibly_damaging(0.811) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PRKCD | insertion | Frame_Shift_Ins | novel | c.1528_1529insAGGAGAAGCAGAGGCTGCTC | p.Gly510GlufsTer21 | p.G510Efs*21 | Q05655 | protein_coding | | | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCD | insertion | Frame_Shift_Ins | novel | c.1989_1990insA | p.Ser664IlefsTer22 | p.S664Ifs*22 | Q05655 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCD | insertion | Nonsense_Mutation | novel | c.1990_1991insTTTAAAATATAAGTTCAGGCCGGGCACAGTGGC | p.Ser664delinsPheTerAsnIleSerSerGlyArgAlaGlnTrpPro | p.S664delinsF*NISSGRAQWP | Q05655 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCD | SNV | Missense_Mutation | rs149165175 | c.604G>A | p.Asp202Asn | p.D202N | Q05655 | protein_coding | tolerated(0.07) | benign(0.105) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCD | SNV | Missense_Mutation | rs782258819 | c.422N>T | p.Thr141Met | p.T141M | Q05655 | protein_coding | tolerated(0.12) | benign(0.107) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | TAE-684 | TAE-684 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | [3H]-PHORBOL 12,13-DIBUTYRATE | CHEMBL27768 | 24794745 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | GO-6976 | GO-6976 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | ETHANOL | ALCOHOL | 1744136 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL565612 | SOTRASTAURIN | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | 178101947 | RUBOXISTAURIN | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | ENOXOLONE | ENOXOLONE | 24461294 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL574737 | UCN-01 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | KAI-9803 | DELCASERTIB | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL608533 | MIDOSTAURIN | |